Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Swift

Showing results (201-210 of 307) with videos related to

Pageof 31
Sort By:
Neurotoxicology|August 15, 2006
The prevalence of cognitive malingering in persons reporting exposure to occupational and environmental substancesKevin W Greve, Kevin J Bianchini, F William Black, et al.
Journal of Equine Veterinary Science|February 19, 2020
Randomized Comparative Trial of Acupuncture and Exercise Versus Uterine Ecbolics in the Treatment of Persistent Postbreeding Endometritis in MaresLaura A Swift, Bruce W Christensen, Mollie B Samocha, et al.
Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists|July 28, 2006
Classification accuracy of the Test of Memory Malingering in persons reporting exposure to environmental and industrial toxins: Results of a known-groups analysisKevin W Greve, Kevin J Bianchini, F William Black, et al.
Childhood Obesity (Print)|December 31, 2015
A Call to Action: Setting the Research Agenda for Addressing Obesity and Weight-Related Topics in Children with Physical DisabilitiesAmy C McPherson, Geoff D C Ball, Désirée B Maltais, et al.
Cancer|January 10, 2001
A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone diseaseJ R Berenson, R Vescio, K Henick, et al.
Neurobiology of Disease|September 15, 2024
Suppression of neuronal AMPKβ2 isoform impairs recognition memory and synaptic plasticityNathaniel A Swift, Qian Yang, Hannah M Jester, et al.
Annals of the New York Academy of Sciences|January 1, 1988
cis-3-(substituted phenyl)-3-(1H-imidazol-1-ylmethyl)-2-methyl-5-([(substituted phenyl)thio(or amino)]methyl)isoxazolidines. In vitro antifungal activity and structure-activity relationshipsT R DeCory, P A Swift, G B Mullen, et al.
Annals of the New York Academy of Sciences|January 1, 1988
3-(substituted phenyl)-3-(1H-1,2,4-triazol-1-ylmethyl)-2-methyl-5- [(substituted phenoxy)methyl]-isoxazolidine derivatives. Structure-activity relationshipsG A Bennett, P A Swift, G B Mullen, et al.
Annals of the New York Academy of Sciences|January 1, 1988
cis-5-alkyl(or alkenyl)-3-phenyl-3-(1H-imidazole-1-ylmethyl)-2- methylisoxazolidine derivatives. In vitro antifungal activity and structure-activity relationshipsP A Swift, G A Bennett, G B Mullen, et al.
Annals of the New York Academy of Sciences|January 1, 1988
In vitro antifungal activity of novel substituted 3,5-diphenyl-3-(1H-1,2,4-triazol-1-ylmethyl)-2- methylisoxazolidine derivativesG A Bennett, P A Swift, G B Mullen, et al.
Pageof 31

Showing results (201-210 of 307) with videos related to

Sort By:
Pageof 31
Neurotoxicology|August 15, 2006
The prevalence of cognitive malingering in persons reporting exposure to occupational and environmental substancesKevin W Greve, Kevin J Bianchini, F William Black, et al.
Journal of Equine Veterinary Science|February 19, 2020
Randomized Comparative Trial of Acupuncture and Exercise Versus Uterine Ecbolics in the Treatment of Persistent Postbreeding Endometritis in MaresLaura A Swift, Bruce W Christensen, Mollie B Samocha, et al.
Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists|July 28, 2006
Classification accuracy of the Test of Memory Malingering in persons reporting exposure to environmental and industrial toxins: Results of a known-groups analysisKevin W Greve, Kevin J Bianchini, F William Black, et al.
Childhood Obesity (Print)|December 31, 2015
A Call to Action: Setting the Research Agenda for Addressing Obesity and Weight-Related Topics in Children with Physical DisabilitiesAmy C McPherson, Geoff D C Ball, Désirée B Maltais, et al.
Cancer|January 10, 2001
A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone diseaseJ R Berenson, R Vescio, K Henick, et al.
Neurobiology of Disease|September 15, 2024
Suppression of neuronal AMPKβ2 isoform impairs recognition memory and synaptic plasticityNathaniel A Swift, Qian Yang, Hannah M Jester, et al.
Annals of the New York Academy of Sciences|January 1, 1988
cis-3-(substituted phenyl)-3-(1H-imidazol-1-ylmethyl)-2-methyl-5-([(substituted phenyl)thio(or amino)]methyl)isoxazolidines. In vitro antifungal activity and structure-activity relationshipsT R DeCory, P A Swift, G B Mullen, et al.
Annals of the New York Academy of Sciences|January 1, 1988
3-(substituted phenyl)-3-(1H-1,2,4-triazol-1-ylmethyl)-2-methyl-5- [(substituted phenoxy)methyl]-isoxazolidine derivatives. Structure-activity relationshipsG A Bennett, P A Swift, G B Mullen, et al.
Annals of the New York Academy of Sciences|January 1, 1988
cis-5-alkyl(or alkenyl)-3-phenyl-3-(1H-imidazole-1-ylmethyl)-2- methylisoxazolidine derivatives. In vitro antifungal activity and structure-activity relationshipsP A Swift, G A Bennett, G B Mullen, et al.
Annals of the New York Academy of Sciences|January 1, 1988
In vitro antifungal activity of novel substituted 3,5-diphenyl-3-(1H-1,2,4-triazol-1-ylmethyl)-2- methylisoxazolidine derivativesG A Bennett, P A Swift, G B Mullen, et al.
Pageof 31